Lyon

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Chronic myeloid leukaemia5 trials
• Lung cancer4 trials
• Colorectal cancer3 trials
• Melanoma3 trials
• Hidradenitis suppurativa2 trials
• Metastatic breast cancer2 trials
• Childhood cancers1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• Familial hypercholesterolaemia1 trial
• Gastric and oesophageal cancer1 trial
• Glioblastoma1 trial
• Head and neck cancer1 trial
• and 8 more

Phase

• Phase 25 trials
• Phase 35 trials
• Phase 12 trials
• Phase 1/22 trials
• Early phase 11 trial

Status

• Active, not recruiting10 trials
• Completed6 trials
• Terminated4 trials
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals20 trials
• Advanced Accelerator Applications1 trial

Running trials

• Recruiting

  Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

  NCT06514534· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Phase 2 Study of Rapcabtagene Autoleucel in Myositis

  NCT06665256· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

  NCT06444087· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

  NCT06092879· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

  NCT06157086· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

  NCT05697146· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

  NCT05544929· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

  NCT04699188· Phase 1/2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Post-Authorization Long-Term Safety Study of LUTATHERA

  NCT03691064· Advanced Accelerator Applications· Source

• Active, not recruiting

  Ribociclib (LEE011) Rollover Study for Continued Access

  NCT02934568· Phase 2· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic myeloid leukaemia1 recruiting

Closed trials

• Completed

  A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France

  NCT07839858· Novartis Pharmaceuticals· Source

• Terminated

  Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

  NCT05358249· Phase 1/2· Novartis Pharmaceuticals· Source

• Terminated

  Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

  NCT04712721· Early phase 1· Novartis Pharmaceuticals· Source

• Completed

  Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

  NCT04948333· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

  NCT04179175· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

  NCT03106779· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

  NCT02974725· Phase 1· Novartis Pharmaceuticals· Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

  NCT01698905· Phase 2· Novartis Pharmaceuticals· Source